Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

David Oupický

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4710-861X; OpenAlex author ID A5016187749. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Tumor Lipidomic Changes after Treatment with Polymeric Hydroxychloroquine in a Syngeneic Murine Model of Pancreatic Cancer. Co-author DOI 10.1021/acsomega.5c05706↗
  2. Structure-Activity Mapping of Intraperitoneal mRNA-LNPs: Decoupling Tumor and Liver Biodistribution in Pancreatic Cancer Last author DOI 10.64898/2026.03.20.712457↗
  3. Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2025.123255↗
  4. Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202207010↗
  5. Polymeric Chloroquine as an Effective Antimigration Agent in the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.2c00596↗
  6. Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acsami.1c21997↗
  7. Gene silencing delivery systems for the treatment of pancreatic cancer: Where and what to target next? Last author DOI 10.1016/j.jconrel.2021.01.020↗
  8. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer. Last author DOI 10.1016/j.jconrel.2021.03.028↗
  9. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.1c00653↗
  10. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. Last author DOI 10.1021/acsnano.9b03978↗
  11. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy. Last author DOI 10.1016/j.pharmthera.2017.05.012↗
  12. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Last author DOI 10.1016/j.biomaterials.2016.05.042↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sudipta Panja · 3 shared papers, 2022–2026 · strength 0.76
  2. Siyuan Tang · 4 shared papers, 2021–2023 · strength 0.60
  3. Hang Yu · 5 shared papers, 2016–2021 · strength 0.56
  4. Rubayat Islam Khan · 3 shared papers, 2021–2025 · strength 0.55
  5. Ling Ding · 3 shared papers, 2021–2022 · strength 0.47
  6. Ying Xie · 4 shared papers, 2016–2021 · strength 0.41
  7. Daryl J. Murry · 1 shared paper, 2026 · strength 0.36
  8. Sai Sundeep Kollala · 1 shared paper, 2026 · strength 0.36
  9. Farhana S. Islam · 1 shared paper, 2026 · strength 0.33
  10. Rakesh K. Singh · 3 shared papers, 2017–2021 · strength 0.30
  11. David Větvička · 2 shared papers, 2021 · strength 0.27
  12. Michael Anthony Hollingsworth · 2 shared papers, 2017–2023 · strength 0.26
  13. Thomas C. Caffrey · 1 shared paper, 2023 · strength 0.18
  14. Seok‐Yeong Yu · 1 shared paper, 2023 · strength 0.18
  15. So‐Youn Kim · 1 shared paper, 2023 · strength 0.18
  16. Richard L. Sleightholm · 2 shared papers, 2017–2020 · strength 0.18
  17. Dipakkumar R. Prajapati · 1 shared paper, 2020 · strength 0.10
  18. Yan Wang · 1 shared paper, 2016 · strength 0.05
  19. Surinder K. Batra · 1 shared paper, 2016 · strength 0.05
  20. Maneesh Jain · 1 shared paper, 2016 · strength 0.05
  21. Sushil Kumar K · 1 shared paper, 2016 · strength 0.05
  22. Satyanarayana Rachagani · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.